WATS Sampling for Stomach Cancer

Recruiting in Palo Alto (17 mi)

Overseen byDouglas Morgan, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Alabama at Birmingham

Stay on Your Current Meds

No Placebo Group

Trial Summary

What is the purpose of this trial?The purpose of this research is to compare the diagnostic yields of the WATS approach versus the updated Sydney protocol (five standard biopsies in the three gastric regions). • We hypothesize that the WATS technology will increase the overall diagnostic yield up to 35% of gastric premalignant lesions and early gastric cancer. To explore the performance of the existing and novel biomarkers, including the IHCs p53 and MUC2. We anticipate concordance of the existing biomarkers as adjuncts to the diagnosis. To accomplish this aim, we will analyze current biomarkers on all study subjects (Aim 1), as well as explore novel gastric biomarkers.

Eligibility Criteria

This trial is for patients who need an upper endoscopy, which is a procedure where a doctor looks inside the stomach. It's designed to test if a new way of sampling cells from the stomach lining can better detect early signs of cancer or precancerous conditions compared to current methods.

Inclusion Criteria

I need an upper endoscopy.

Participant Groups

The study tests WATS (Wide-area Trans-epithelial Sampling) technology against the standard Sydney protocol involving five biopsies in different stomach areas. The goal is to see if WATS improves detection rates by up to 35% for early gastric cancer and pre-cancer lesions.

1Treatment groups

Experimental Treatment

Group I: Patients Scheduled for Standard of Care Upper EndoscopyExperimental Treatment1 Intervention